ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO927

The Circulating Exosomal MicroRNAs Related to Albuminuria in Patients with Diabetic Nephropathy

Session Information

Category: Diabetic Kidney Disease

  • 602 Diabetic Kidney Disease: Clinical

Authors

  • Kim, Hyoshik, Soonchunhyang University Seoul Hospital, Soonchunhyang University Medical College, Seoul, Republic of Korea, Seoul, Korea (the Republic of)
  • Kim, Yon hee, Soonchunhyang University Seoul Hospital, Soonchunhyang University Medical College, Seoul, Republic of Korea, Seoul, Korea (the Republic of)
  • Noh, Hyunjin, Soonchunhyang University Seoul Hospital, Soonchunhyang University Medical College, Seoul, Republic of Korea, Seoul, Korea (the Republic of)
  • Park, Moo Yong, Soonchunhyang University Hosptial, Bucehon, Korea (the Republic of)
  • Kwon, Soon hyo, Soonchunhyang University Seoul Hospital, Soonchunhyang University Medical College, Seoul, Republic of Korea, Seoul, Korea (the Republic of)
Background

Diabetic nephropathy (DN) is associated with high risk of cardiovascular disease and
mortality. Exosomal microRNAs (miRNAs) regulate gene expression in a variety of
tissues and play important roles in the pathology of various diseases. We hypothesized
that the exosomal miRNA profile would differ between DN patients and patients without
nephropathy.

Methods

We prospectively enrolled 74 participants, including healthy volunteers (HVs), diabetic
patients without nephropathy, and those with DN. The serum exosomal miRNA profiles
of participants were examined using RNA sequencing.

Results

The expression levels of 107 miRNAs differed between HVs and patients without DN, whereas the expression levels of 95 miRNAs differed between HVs and patients with DN. Among these miRNAs, we found 7 miRNAs (miR-1246, miR-642a-3p, let-7c-5p, miR-1255b-5p, let-7i-3p, miR-5010-5p, miR-150-3p) that were uniquely up-regulated in DN patients compared to HVs, and miR-4449 that was highly expressed in DN patients compared to patients without DN. A pathway analysis revealed that these eight miRNAs are likely involved in MAPK signaling, integrin function in angiogenesis, and regulation of the AP-1 transcription factor. Moreover, they were all significantly correlated with the degree of albuminuria (figure 1).

Conclusion

Patients with DN have a different serum exosomal miRNA profile compared to HVs and
these miRNAs may be promising candidates for the diagnosis and treatment of DN and
cardiovascular disease.

Correlation between miRNAs and albuminuria
Mature miRNAs albuminuria (r/p-value)
miR-1246 0.373/0.001
miR-642a-3p 0.362/0.002
let-7c-5p 0.428<0.001
miR-1255b-5p 0.240<0.039
let-7i-3p 0.300/0.009
miR-5010-5p 0.254/0.029
miR-150-3p 0.347/0.002
miR-4449 0.497/<0.001